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The major burden of both chronic obstructive pulmonary disease 
(COPD) and pulmonary tuberculosis (PTB) occurs in low- and 
middle-income countries. Ninety percent of the estimated 3 million 
annual deaths from COPD, and a large majority of the 9 million cases 
of active PTB, occur in these countries.[1] In these populations, factors 
other than cigarette smoking (e.g. biomass fuel and occupational 
exposures) contribute to the pathogenesis of COPD.[2] In a number 
of large population-based cross-sectional studies, PTB has also been 
shown to be strongly associated with the presence of chronic airflow 
limitation (CAL).[3-6] In some studies, this association is almost as 
strong as that for cigarette smoking.[5-7] In a community-based study 
performed in South Africa (SA), 49.2% of adults aged ≥40 years who 
reported a history of PTB had evidence of CAL (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stage 1 or higher).[8]
The mechanisms responsible for CAL following PTB are unclear. 
Resolution of PTB is characterised by exuberant fibrosis, resulting in 
bronchiectasis, fibrocystic areas and shrinkage of affected lobes. It 
has been assumed that CAL in healed PTB is caused by a combination 
of bronchiectasis, large-airway (bronchial) stenosis and distortion 
of large airways,[9-12] but detailed study of the pathophysiology is 
lacking. We have examined the pathophysiology of CAL in patients 
with previous PTB identified in an SA community-based prevalence 
study and describe a pattern of pathophysiology that may differ from 
that in patients with COPD not associated with previous PTB. These 
findings warrant further study in order to establish whether PTB-
associated CAL should be regarded as a phenotype of COPD.
Methods
In a community-based cross-sectional study performed in 2005, 
we randomly sampled 15% of all non-institutionalised adults aged 
>40 years from two low-income suburbs of Cape Town, SA. The 
subjects were all coloured (i.e. of mixed ancestry)[13] and were 
assessed for CAL using the Burden of Obstructive Lung Disease 
(BOLD) methodology.[14] One hundred and ninety-six subjects were 
identified as having post-bronchodilator airflow obstruction on 
handheld spirometry (forced expiratory volume in 1 second (FEV1)/
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Background. An association between chronic airflow limitation (CAL) and a history of pulmonary tuberculosis (PTB) has been confirmed 
in epidemiological studies, but the mechanisms responsible for this association are unclear. It is debated whether CAL in this context should 
be viewed as chronic obstructive pulmonary disease (COPD) or a separate phenotype.
Objective. To compare lung physiology and high-resolution computed tomography (HRCT) findings in subjects with CAL and evidence of 
previous (healed) PTB with those in subjects with smoking-related COPD without evidence of previous PTB.
Methods. Subjects with CAL identified during a Burden of Obstructive Lung Disease (BOLD) study performed in South Africa were studied. 
Investigations included questionnaires, lung physiology (spirometry, body plethysmography and diffusing capacity) and quantitative HRCT 
scans to assess bronchial anatomy and the presence of emphysema (<–950 HU), gas trapping (<–860 HU) and fibrosis (>–200 HU). Findings 
in subjects with a past history and/or HRCT evidence of PTB were compared with those in subjects without these features.
Results. One hundred and seven of 196 eligible subjects (54.6%) were enrolled, 104 performed physiology tests and 94 had an HRCT 
scan. Based on history and HRCT findings, subjects were categorised as no previous PTB (NPTB, n=31), probable previous PTB (n=33) 
or definite previous PTB (DPTB, n=39). Subjects with DPTB had a lower diffusing capacity (Δ=–17.7%; p=0.001) and inspiratory capacity 
(Δ=–21.5%; p=0.001) than NPTB subjects, and higher gas-trapping and fibrosis but not emphysema scores (Δ=+6.2% (p=0.021), +0.36% 
(p=0.017) and +3.5% (p=0.098), respectively).
Conclusions. The mechanisms of CAL associated with previous PTB appear to differ from those in the more common smoking-related 
COPD and warrant further study.
S Afr Med J 2017;107(5):440-445. DOI:10.7196/SAMJ.2017.v107i5.12118
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forced vital capacity (FVC) ratio <0.7), and form the study popu lation 
for the current study. The vital status of all subjects was established, 
and those still alive were invited to participate. Exclusion criteria 
were active tuberculosis (TB), advanced or untreated malignancy, 
dementia, substance abuse, or any other condition that in the opinion 
of the investigators would place the subject at undue risk.
Between March 2010 and February 2011, eligible subjects under-
went clinical evaluation and completed the BOLD questionnaires 
and a questionnaire with more detailed questions about previous 
PTB. At a second visit, subjects completed the St George’s Respiratory 
Questionnaire (SGRQ), the Medical Research Council (MRC) 
dyspnoea score was calculated, and spirometry after respiratory 
medication withhold was performed using an nSpire spirometer 
(Ferraris, USA) before and after administration of both ipratropium 
bromide (80 μg) and salbutamol (400 μg) via a pressurised metered-
dose inhaler. Diffusing capacity for carbon monoxide (DLCO) was 
measured by the single-breath method using a VMAX 2130 system 
(Sensormedics, USA). Two weeks later, spirometry before and after 
bronchodilator and whole-body plethysmography were performed 
according to American Thoracic Society/European Respiratory 
Society recommendations[15] by qualified respiratory technologists 
blinded to patient clinical information, and a non-contrast high-
resolution chest computed tomography scan (HRCT) was performed 
by a single experienced radiographer. Images were obtained at total 
lung capacity (TLC) and residual volume (RV). Quantitative analysis 
of scans using customised software (MedQIA, USA) was performed 
by investigators blinded to clinical information. Percentages of 
low-attenuation areas (LAAs) <–950 HU and high-attenuation 
areas (HAAs) >200 HU were used to determine the emphysema 
and fibrosis scores, respectively. On the RV scan, the percentage of 
LAAs <–860 HU was used to determine the gas trapping score. The 
corrected gas trapping score (CGTS) was calculated by subtracting 
the emphysema score (at TLC) from the gas trapping score (at RV).
Using Cirrus Lung 13.05 software (Diagnostic Image Analysis 
Group, Netherlands), the average wall thickness and percentage wall 
area of the 4th- and 5th-generation bronchi were measured, and the 
aggregated airway diameter for individual patients was expressed as the 
standardised thickness of an airway of inner perimeter 10 mm (Pi10).
Subjects with a history of treated PTB were designated as definite 
previous TB (DPTB). HRCT scans were viewed by two experienced 
radiologists for lesions suggesting previous PTB. Subjects without a 
history of PTB but with positive scans were designated as probable 
previous TB (PPTB). Subjects with neither a history of PTB nor HRCT 
scan evidence of PTB were designated as no previous TB (NPTB).
Ethics approval
Ethics approval for the study was obtained from the Human Research 
Ethics Committee of the University of Cape Town (ref. no 441/2009), 
Stellenbosch University (ref. no. N/09/11/328) and local health 
authorities (ref. no. 10165), and all the subjects provided written 
informed consent.
Statistical analysis
Statistical analysis of the between-group comparisons of lung 
physiology and imaging was performed using STATA version 12.1 
(StataCorp, USA). Parametric and non-parametric tests were used in 
univariate analyses. Multivariate analysis involved linear regression 
with covariates stated in the relevant tables below. Missing data 
points were not imputed and were not included in the analysis. A 
significance level of p<0.05 was chosen, and all statistical tests were 
two-sided.
Results
Of the 196 subjects identified with CAL in 2005, 45 (23.0%) had 
died, 11 (5.6%) had moved from the region, 19 (9.7%) declined 
participation, and 14 (7.1%) were excluded for medical reasons 
(Fig. 1); 107 subjects were therefore enrolled, of whom 3 withdrew 
after the first visit. The mean age was 63.1 years (range 46 - 83), 49 
(45.8%) were men, and none were HIV-positive. Of the 104 parti-
cipants, 39 (37.5%) were classified as DPTB, 34 (32.7%) as PPTB and 
31 (29.8%) as NPTB.
The baseline demographics of the groups were similar (age, sex, 
smoking status, number of pack-years of smoking, cannabis use, 
symptoms of chronic bronchitis, or past diagnosis of asthma). Of the 
subjects with features of asthma (n=17), 12 (70.6%) were smokers. No 
subjects had significant exposure to biomass fuels (Table 1).
Total SGRQ and MRC dyspnoea scores were not significantly 
different between the groups. CAL was not confirmed in 17 of 
103 subjects (16.5%), 9 NPTB, 7 PPTB and 1 DPTB. Between-
group differences in mean percentage of predicted FEV1 (p=0.053), 
FVC (p=0.990), and FEV1 bronchodilator responsiveness were not 
statistically significant (Table 2).
Inspiratory capacity (IC) was significantly lower in subjects with 
DPTB and PPTB than in those with NPTB, and expiratory reserve 
volume (ERV) and functional residual capacity (FRC) were higher. 
TLC, RV and RV/TLC were not different between the groups (Table 2 
and Fig. 2). These differences remained when subjects without CAL 
were removed from the analysis (Table 3). On multivariate analysis, 
the IC was 21.5% (95% confidence interval (CI) –33.43 - –9.63) 
and 20.8% (CI –32.87 - –8.63) lower in the DPTB group and PPTB 
groups, respectively, compared with the NPTB group (Table 4). 
The DLCO was significantly lower in subjects with both DPTB 
and PPTB. On multivariate analysis, DLCO (% predicted) was 17.7% 
(CI  –27.91 - –7.57) and 10.9% lower (95% CI –21.14 - – 0.58) in 
DPTB and PPTB, respectively, than in NPTB (Tables 2 and 4, Fig. 2).
HRCT fibrosis scores in DPTB, but not PPTB, were significantly 
higher than in NPTB, being 0.36% (95% CI 0.06 - 0.65; p=0.017) 
higher on multivariate analysis, but overall scores were low (Tables 4 
and 5). Analysis by lobe confirmed that only in the right upper lobe 
(RUL) was the fibrosis score significantly higher (data not shown). 
Emphysema scores were non-significantly greater in the DPTB group, 
for both uni- and multivariate analysis (Tables 3 and 4).
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Fig. 1. Study enrolment and division into groups based on previous PTB status.
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The mean gas trapping score on expir-
ation was higher in both the DPTB (38.9%) 
and PPTB groups (32.8%) compared with 
the NPTB group (26.7%; p=0.006). The 
median CGTS (calculated by subtracting 
the emphysema score from the gas trapping 
score) in the DPTB group was higher than 
in the PPTB and NPTB groups on univariate 
analysis (p=0.011), and also higher than in 
the NPTB group  on multivariate analysis 
(p=0.021) (Tables 4 and 5).
No between-group differences in measures 
of airway thickness (Pi10, average wall thick-
ness of the 4th- and 5th-generation bron-
chi, average percentage wall area of the 4th- 
(WT4) and 5th-generation bronchi) were 
observed (Table 5). However, the WT4 in the 
RUL in DPTB and PPTB subjects combined 
was higher than in NPTB subjects (median 
0.80 mm; (interquartile range (IQR) 0.6 - 
1.1) v. 0.67 mm (IQR 0.55 - 0.79); p=0.036).
Discussion
This study, performed in a low- to middle-
income population with a high prevalence of 
TB, suggests that there are differences in the 
mechanisms of airflow limitation in subjects 
with previous TB compared with the more 
common smoking-related COPD. The most 
significant differences in TB-associated 
obstructive pulmonary disease (TOPD) were 
more evidence of static gas (air) trapping 
on lung function testing and quantitative 
HRCT, and a lower DLCO.
The physiological evidence for static gas 
trapping in TOPD was lower IC (21.5% 
lower), higher FRC and higher ERV com-
pared with subjects with COPD without this 
history, while no differences in TLC, RV and 
RV/TLC were observed.
Together, these findings suggest a com-
bination of pathologies in TOPD. First is 
Table 1. Baseline characteristics according to PTB category
NPTB (N=31) PPTB (N=34) DPTB (N=39) p-value
Age (years)
Mean (range) 62.9 (46.4 - 82.7) 64.9 (51.3 - 79.0) 61.6 (47.9 - 81.9)
Median 61.4 67.3 59.8 0.283 (K-W)
Male, n (%) 12 (38.7) 14 (41.2) 23 (59.0) 0.169 (χ2)
Cigarette smoking
Current, n (%) 11 (35.5) 20 (58.8) 23 (59.0)
Previous, n (%) 13 (41.9) 11 (32.4) 14 (35.9)
Never, n (%) 7 (22.6) 3 (8.8) 2 (5.1) 0.125 (Fisher)
Pack-years, mean (SD), median (IQR) 20.8 (23.4),
13.1 (1.0 - 31.2)
22.9 (19.5),
19.9 (9.5 - 35.5)
26.3 (24.2),
22.0 (14.6 - 32.5)
0.270 (K-W)
Cannabis smoking
Current/previous, n (%) 9 (29.0) 8 (23.5) 14 (35.9) 0.512 (χ2)
Joint-years, median (IQR) 0 (0 - 0.14) 0 (0 - 0) 0 (0 - 19) 0.421 (K-W)
Chronic bronchitis, n (%) 5 (16.1) 9 (26.5) 16 (41.0) 0.069 (χ2)
Features of asthma, n (%)* 7 (22.6) 6 (17.6) 4 (10.3) 0.341 (χ2)
 Features of asthma with current/previous 
smoking, n (%)
5 (16.1) 4 (11.8) 3 (7.7) 1.000 (Fisher)
Chronic respiratory medication use, n (%)
SABA 8 (25.8) 10 (29.4) 13 (33.3) 0.790 (χ2)
SAMA 3 (9.7) 2 (5.9) 5 (12.8) 0.605 (χ2)
LABA 1 (3.2) 2 (5.9) 1 (2.6) 0.746 (χ2)
ICS 6 (19.4) 6 (17.7) 5 (12.8) 0.740 (χ2)
Theophylline 3 (9.7) 3 (8.8) 4 (10.3) 0.043 (χ2)
Comorbidity, n (%) 
Hypertension 17 (54.8) 15 (44.1) 17 (43.6) 0.589 (χ2)
Diabetes 5 (16.1) 4 (11.8) 4 (10.3) 0.752 (χ2)
Hypercholesterolaemia 6 (19.4) 2 (5.9) 2 (5.1) 0.089 (χ2)
Arthritis 6 (19.4) 7 (20.6) 3 (7.7) 0.240 (χ2)
IQR = interquartile range; SABA = short-acting beta-agonist; SAMA = short-acting antimuscarinic agent; LABA = long-acting beta-agonist; ICS = inhaled corticosteroid;  
K-W = Kruskal-Wallis test; χ2 = χ2 test; Fisher = Fisher’s exact test.
*Missing data for 1 patient.
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Fig. 2. Comparison of subjects with NPTB, PPTB and DPTB: (A) FEV1; (B) IC; (C) DLCO; (D) CGTS on 
HRCT scan. Box-and-whisker plots. (CGTS = (gas trapping score on expiratory CT scan) – (emphysema 
score on inspiratory CT scan); % pred = percentage of predicted; ANOVA = analysis of variance; K-W = 
Kruskal-Wallis test.)
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emphysema with gas trapping only evident on expiratory HRCT 
scans. The gas trapping is probably caused by cicatricial narrowing of 
small airways, without major involvement of the larger airways in this 
population. This is supported by the lack of difference in quantitative 
measurements of larger airway dimensions on HRCT, which for 
technical reasons only includes the first five airway generations. 
Notably, there was no evidence of bronchiectasis or stenosis of large 
and medium-sized airways in any of the subjects. The observed 
increase in the gas trapping score in TOPD measured by quantitative 
HRCT was also not accounted for by a greater emphysema score at 
TLC. Additionally, the small observed increase in the fibrosis score in 
TOPD subjects was mainly accounted for by the RUL (the lobe most 
frequently involved in PTB), but did not influence the TLC, implying 
lack of significant fibrotic restriction.
A second significant finding was the reduction in DLCO in subjects 
with TOPD. Although commonly reduced in COPD and correlated 
Table 2. Comparison of symptoms and lung physiology according to PTB status
NPTB (N=31) PPTB (N=34) DPTB (N=39) p-value
MRC dyspnoea score, mean (SD) 2.87 (1.5) 2.88 (1.7) (n=33) 3.03 (1.4) (n=38) 0.547 (ANOVA)
SGRQ total score, median (IQR) 32.6 (14.2 - 48.1) 35.1 (7.5 - 58.7) 34.6 (21.1 - 57.9) 0.836 (K-W)
Spirometry
n 31 33* 39
Post-BD FEV1 (% pred), mean (SD) 75.1 (18.3) 71.9 (20.2) 63.0 (24.9) 0.053 (ANOVA)
Post-BD FVC (% pred), mean (SD) 96.3 (11.3) 96.2 (15.5) 95.8 (19.2) 0.990 (ANOVA)
Post-BD FEV1/FVC, median 0.67 0.63 0.54 0.002 (K-W)
Subjects with FEV1/FVC ≥0.70, n (%) 9 (29.0) 7 (21.2) 1 (2.6) 0.008 (χ2)
Response to bronchodilator 
Change in FEV1 (L), median (IQR) 0.20 (0.12 - 0.27) 0.19 (0.07 - 0.28) 0.16 (0.08 - 0.26) 0.879 (K-W)
Subjects with reversibility, n (%) 13 (41.9) 14 (42.4) 12 (30.7) 0.511 (χ2)
Diffusing capacity
DLCO (mL/min/mmHg), mean (SD) 18.1 (5.5) 15.4 (5.2) 14.9 (4.8) 0.033 (ANOVA)
DLCO (% pred), mean (SD) 79.5 (23.7) 68.6 (23.3) 61.7 (15.3) 0.003 (ANOVA)
Plethysmography
n 29† 32† 38†
TLC (% pred), median (IQR) 102 (92 - 109) 103 (90 - 112.5) 102 (93 - 118) 0.795 (K-W)
IC (% pred), median (IQR) 120 (103 - 128) 99.5 (83.5 - 114.5) 92 (76 - 103) 0.0001 (K-W)
FRC (% pred), median (IQR) 103 (85 - 114) 110 (96.5 - 137.5) 121.5 (110 - 142) 0.002 (K-W)
ERV (% pred), median (IQR) 22 (12 - 46) 51.5 (37 - 92) 73 (28 - 101) 0.0001 (K-W)
RV (% pred), median (IQR) 133 (108 - 150) 130.5 (118.5 - 151) 139 (122 - 179) 0.248 (K-W)
RV/TLC (%), median (IQR) 51 (46 - 54) 51.5 (49 - 56.5) 55.5 (44 - 61) 0.161 (K-W)
SD = standard deviation; IQR = interquartile range; BD = bronchodilator; % pred = percentage of predicted; IC = inspiratory capacity; FRC = functional residual capacity;  
ERV = expiratory reserve volume; ANOVA = analysis of variance; K-W = Kruskal-Wallis test; χ2 = χ2 test.
*One subject not able to perform spirometry.
†Five subjects not included in plethysmography for technical reasons.
Table 3. Lung physiology results according to PTB status for subjects with CAL at first visit*
NPTB PPTB DPTB p-value
Spirometry
n 22 26 38
Post-BD FEV1 (% pred), mean (SD) 69.6 (17.9) 68.5 (20.5) 62.7 (25.2) 0.423 (ANOVA)
Post-BD FVC (% pred), mean (SD) 97.0 (12.7) 97.9 (15.7) 96.2 (19.3) 0.926 (ANOVA)
Post-BD FEV1/FVC (median) 0.59 0.60 0.54 0.113 (K-W)
Diffusing capacity
n 22 26 38
DLCO (mL/min/mmHg), mean (SD) 17.9 (6.2) 15.1 (5.2) 14.9 (4.8) 0.088 (ANOVA)
DLCO (% pred), mean (SD) 78.3 (24.4) 67.0 (23.1) 61.7 (15.5) 0.013 (ANOVA)
Plethysmography
n 21 25 37
TLC (% pred), median (IQR) 103 (94 - 113) 106 (92 - 116) 102 (97 - 118) 0.996 (K-W)
RV (% pred), median (IQR) 135 (117 - 156) 135 (124 - 157) 141 (125 - 179) 0.681 (K-W)
RV/TLC (%), mean (SD) 50.8 (7.0) 52.4 (6.5) 54.1 (10.1) 0.345 (ANOVA)
IC (% pred), median (IQR) 119 (103 - 127) 97 (85 - 112) 92 (78 - 103) 0.0004 (K-W)
ERV (% pred), median (IQR) 26 (14 - 63) 58 (37 - 101) 69 (37 - 90) 0.005 (K-W)
FRC (% pred), median (IQR) 105 (94 - 115) 114 (99 - 141) 122 (110 - 142) 0.046 (K-W)
BD = bronchodilator; SD = standard deviation; IQR = interquartile range; % pred = percentage of predicted; ANOVA = analysis of variance; K-W = Kruskal-Wallis test.
*Subjects no longer found to have FEV1/FVC <0.7 are excluded in this analysis. The excluded subjects all had reported FEV1/FVC <0.7 in the initial study performed in 2005.
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with the presence of emphysema, in our study of patients with TOPD, 
the DLCO was 17.7% lower than in the control group with COPD, 
although emphysema scores in these individuals were not significantly 
higher. An alternative hypothesis for this reduction in DLCO is the 
attenuation of the pulmonary vasculature within the bronchovascular 
bundles surrounding the small airways, resulting in ventilation/
perfusion mismatch. Fibrosis in this location may compromise the 
pulmonary vasculature and increase pulmonary resistance, resulting 
in pulmonary hypertension, which is known to be more common after 
PTB than in the more common forms of COPD.[16,17]
The proposal that the small airways are the major site of pathology 
in healed PTB is supported by HRCT findings in the active phase of 
PTB, in which centrilobular or ‘tree-in-bud’ patterns are found in 
95% of patients. These lesions are usually not evident on conventional 
chest radiographs, but are much more extensive than anticipated 
using HRCT scans.[18,19] An alternative hypothesis for CAL following 
PTB is that persistence of mycobacterial antigens induces or acts as 
a co-factor with smoking and environmental factors such as bio mass 
fuel or pollution, sustaining chronic airway inflammation that in due 
course results in bronchial narrowing with or without paren chymal 
destruc tion. Serum levels of soluble inter leukin-2R, inter leukin-6, 
tumour necrosis factor-alpha, and inter feron-gamma in COPD pati-
ents with TB have been reported to be significantly higher than those 
in patients with COPD alone.[20,21]
Study limitations
Our study has a number of limitations. Firstly, the ideal study 
design to explore differences in mechanisms and answer questions 
surrounding temporality would be a prospective population-based 
cohort of subjects both exposed and not exposed to TB who 
subsequently develop CAL. Our CAL cohort was detected in the 
BOLD community-based survey of randomly selected subjects who 
were not seeking healthcare, resulting in a cohort with a wide range 
of severities of CAL, some with features of asthma as a confounding 
factor, but homogeneous in terms of ethnicity, income and education, 
and living within a relatively small geographical location. Their 
domestic, environmental and other exposures and the impact of 
other confounding factors, both known and unknown, were likely 
to have been similar. Fortuitously, the proportions of subjects in 
the three groups were similar, and the fact that the intermediate 
group (PPTB) showed features similar to the DPTB group for most 
endpoints supports the conclusions of the study.
A further weakness attributable to the design is the numerical (but 
not statistically significant) differences in FEV1 and smoking histories 
Table 4. Multivariate analysis* – DPTB and PPTB v. NPTB
DPTB p-value PPTB p-value
IC (% pred) (CI) –21.53 (–33.43 - –9.63) 0.001 –20.75 (–32.87 - –8.63) 0.001
DLCO (% pred) (CI) –17.74 (–27.91 - –7.57) 0.001 –10.86 (–21.14 - –0.58) 0.039
Emphysema score (% of both lungs), (CI) 3.48 (–0.65 - 7.62) 0.098 –0.07 (–4.26 - 4.12) 0.973
Fibrosis score (% of both lungs), (CI) 0.36 (0.06 - 0.65) 0.017 0.02 (–0.28 - 0.31) 0.91
CGTS (% of both lungs),  (CI) 6.19 (0.98 - 11.41) 0.021 4.78 (–0.51 - 10.06) 0.076
% pred = percentage of predicted; CGTS = (gas trapping score on expiratory CT scan) – (emphysema score on inspiratory CT scan).
*Covariates adjusted for age, sex, cigarette smoking (pack-years), cannabis use (joint-years), features of asthma.
Table 5. Univariate analysis of quantitative lung imaging
NPTB PPTB DPTB p-value
Parenchymal assessment*
n 28 31 35
Lung volumes at TLC
RUL volume (% of TLV), median 22.6 20.1 19.8 0.102 (K-W)
LUL volume (% of TLV), median 23.4 24.4 24.3 0.804 (K-W)
Lung density scores
Emphysema score (% of both lungs), mean (SD) 24.0 (7.1) 24.3 (10.2) 28.6 (8.1) 0.062 (ANOVA)
Fibrosis score (% of both lungs), median (IQR) 2.1 (1.8 - 2.5) 2.1 (1.7 - 2.4) 2.3 (2.0 - 2.7) 0.055 (K-W)
Gas trapping (% of both lungs), mean (SD) 26.7 (13.0) 32.8 (15.5) 38.9 (15.1) 0.006 (ANOVA)
CGTS (% of both lungs), median (IQR) 1.7 (–4.2 - 6.6) 6.1 (1.4 - 14.6) 9.1 (2.1 - 19.6) 0.011 (K-W)
Airway assessment†
Pi10, median (IQR) 2.53 (2.2 - 2.74)
(n=30)
2.45 (2.26 - 2.89)
(n=32)
2.36 (2.01 - 2.82)
(n=37)
0.713 (K-W)
WA4%, median (IQR) 49.6 (46.1 - 55.9)
(n=30)
50.3 (45.1 - 56.3)
(n=32)
50.9 (45.6 - 54.5)
(n=37)
0.941 (K-W)
WA5%, median (IQR) 46.6 (42.5 - 52.6)
(n=30)
49.9 (42.5 - 54.2)
(n=32)
45.7 (38.9 - 51.1)
(n=39)
0.378 (K-W)
WT4 (mm), median (IQR) 0.83 (0.72 - 0.92)
(n=30)
0.83 (0.75 - 0.94)
(n=31)
0.85 (0.79 - 0.96)
(n=38)
0.197 (K-W)
WT5 (mm), median (IQR) 0.69 (0.62 - 0.81)
(n=30)
0.72 (0.62 - 0.79)
(n=31)
0.65 (0.60 - 0.80)
(n=37)
0.896 (K-W)
LUL = left upper lobe; RUL = right upper lobe; SD = standard deviation; IQR = interquartile range; CGTS = (gas trapping score on expiratory CT scan) – (emphysema score on inspiratory CT 
scan); WA4% and WA5% = average percentage wall area of 4th- and 5th-generation bronchi, respectively; WT4 and WT5 = average wall thickness of 4th- and 5th-generation bronchi, respectively; 
K-W = Kruskal-Wallis test; ANOVA = analysis of variance.
*Nine inspiratory scans technically unsuitable for quantitative assessment.
†Five scans technically unsuitable for quantitative airway assessment.
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between the DPTB group and the other two groups, which may have 
accounted for some of the other observed between-group differences 
in physiology. However, the pattern observed across endpoints 
suggests the within-group validity of the mechanisms of airflow 
limitation proposed in patients with DPTB, regardless of between-
group comparisons. This is borne out by the consistency of findings 
in multivariate analysis (where smoking pack-years are adjusted for) 
and in sensitivity analyses, where subjects without CAL were removed. 
There are a number of possible reasons for the finding of absence of 
CAL, as defined by a low FEV1/FVC ratio, in 16.5% of subjects, who 
had previously been found to be obstructed. These include discrepant 
rates of decline in FEV1 compared with FVC, measurement error, and 
potentially physiological improvement. It is important to note that lung 
function improvement has been described in a small proportion of 
subjects in several of the larger COPD cohorts.[22,23]
Other weaknesses are the small sample size and potential selection 
bias. In the 2005 BOLD study, the response rate was 63%,[14] and in the 
current follow-up study it was 53%, with 23% of eligible subjects having 
died. Some of the latter, in whom no cause of death was obtained, may 
have died from complications of CAL. The small sample size prevents 
assessment of other potential mechanisms of CAL in patients with 
COPD such as the role of chronic inflammation, potential synergic 
roles of smoking and retained mycobacterial antigens, bacterial 
colonisation and infections. Finally, the method of determining 
previous PTB status is a potential additional weakness. History 
alone tends to underestimate and HRCT probably overestimates the 
prevalence of TB.[6] Confirmation of bacteriologically proven PTB 
was not possible in this community. Interferon-gamma release assays 
and tuberculin skin testing were not performed, as these have been 
shown to be uninformative in adults in a high-TB setting.[24,25] It was 
also not possible to assess causality of CAL by PTB, or suscepti bility 
to PTB in COPD. There are, however, limited published data, some 
from longitudinal studies, suggesting that both relationships exist. [26-29] 
However, in spite of these limitations we suggest that our study serves 
as an important first step towards investigating differ ences between 
TOPD and more common forms of COPD.
Conclusions
Globally, survivors of PTB may number many millions. Our popu-
lation-based study provides a glimpse of the potential magnitude 
of the importance of TB as a cause of CAL in areas with a 
high prevalence of TB, and of possible disease mechanisms that 
distinguish TB-associated CAL from more common forms of 
COPD. We suggest that TOPD is characterised by gas trapping 
without overall hyperinflation, probably resulting from fibrosis 
surrounding small airways, and reduced diffusing capacity possibly 
reflecting pulmonary vascular (small-vessel) involvement. It may be 
appropriate to use the term TOPD for patients with this association, 
and to consider it a phenotype of COPD. This form of COPD requires 
further prospective study to examine whether these physiological 
and radiological differences translate into differences in prognosis or 
response to therapy.
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